Pediatric Brain Tumor Clinical Trial
— HYPEOfficial title:
High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study (HYPE)
NCT number | NCT05740839 |
Other study ID # | 22-505 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | December 4, 2023 |
Est. completion date | May 31, 2025 |
The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors. The names of the study interventions involved in this study are/is: - High-Intensity Interval Training (HIIT)
Status | Recruiting |
Enrollment | 30 |
Est. completion date | May 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 39 Years |
Eligibility | Inclusion Criteria: - Written informed consent prior to any study-related procedures. - At time of study are a young adult, aged 18-39 years. - Histologically diagnosed brain tumor during childhood (diagnosed =18 years). - Are at least 2 years post tumor-directed therapy. - The effects of exercise on the developing fetus are unknown. For this reason, women of child-bearing potential must agree to undergo a pregnancy test and to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately. - Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist. - Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases. - Speak English and/or Spanish. - Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week. - Does not smoke or vape (no smoking/vaping during previous 12 months). - Willing to travel to DFCI for necessary data collection. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Diagnosis of primary spinal cord tumor. - Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise. - Patients with active malignancies. - Patients who are pregnant. - Actively on a weight loss diet. - Participate in more than 60 minutes of moderate or vigorous structured exercise/week. - Currently smokes or vapes. - Unable to travel to DFCI for necessary data collection. - May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute | Pedals For Pediatrics, Stahl Family Charitable Foundation, The Childhood Brain Tumor Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Attendance of Exercise Sessions | Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions. | From first exercise session to final exercise session, up to 16 weeks | |
Primary | Completion in Minutes of Exercise Sessions | Defined as participant completion of >= 70% of the 90 minutes of exercise per week | From first exercise session to final exercise session, up to 16 weeks | |
Primary | HIIT Compliance | Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute | From first exercise session to final exercise session, up to 16 weeks | |
Primary | Barriers to Exercise Adherence | Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree. | From first exercise session to final exercise session, up to 16 weeks | |
Primary | Participant Burden | Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree. | From first exercise session to final exercise session, up to 16 weeks | |
Secondary | Cognition | An assortment of tests will be executed through the NIH toolbox to measure overall cognition. | : From baseline to post-intervention, up to 43 weeks | |
Secondary | Cardiorespiratory Fitness | Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA). | From baseline to post-intervention, up to 43 weeks | |
Secondary | Muscular Strength | 10-repetition maximum will be used to assess muscular strength. | From baseline to post-intervention, up to 43 weeks | |
Secondary | Body Composition | Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences.
BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight. |
From baseline to post-intervention, up to 43 weeks | |
Secondary | Fatigue | BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness. | From baseline to post-intervention, up to 43 weeks | |
Secondary | Psychosocial Health | Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors | From baseline to post-intervention, up to 43 weeks | |
Secondary | Quality of Sleep | Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants. | From baseline to post-intervention, up to 43 weeks | |
Secondary | Dietary Assessment, ASA-24 | Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool. | Up to 3 days | |
Secondary | ActiGraph - Physical Activity Monitoring | Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion. | From baseline to post-intervention, up to 27 weeks | |
Secondary | Exercise Tolerance | Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session. | From baseline to week 16, up to 32 weeks | |
Secondary | Pain Index | BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning. | From baseline to post-intervention, up to 43 weeks | |
Secondary | Hip and Waist Circumference | Hip and waist circumference will be assessed and recorded in cm. | From baseline to post-intervention, up to 43 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03068832 -
Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
|
Phase 1 | |
Terminated |
NCT03330197 -
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Recruiting |
NCT05367076 -
Fitness to Aid the Brain and Cognitive Skills
|
N/A | |
Completed |
NCT03615404 -
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
|
Phase 1 | |
Completed |
NCT04351035 -
National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry
|
||
Completed |
NCT01707836 -
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
|
N/A | |
Withdrawn |
NCT03577600 -
Compassionate Treatment in Children With Brain Tumors With the Cytotron®
|
N/A | |
Completed |
NCT04659421 -
Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas
|
Phase 2 | |
Active, not recruiting |
NCT03739372 -
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
|
N/A | |
Recruiting |
NCT05887882 -
Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
|
Phase 1 | |
Suspended |
NCT03334162 -
Playful Sensorimotor Training in Pediatric Brain Tumor Patients
|
N/A | |
Withdrawn |
NCT01861990 -
Valproic Acid in Childhood Progressive Brain Tumors
|
Phase 1 | |
Recruiting |
NCT06226519 -
Integrated PET/MRI and Germline Variants to Differentiate Brain Tumopr Recurrence From Iatrogenicchanges in Children
|
||
Terminated |
NCT03591861 -
Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis
|
N/A | |
Completed |
NCT04944875 -
Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging.
|
N/A | |
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
Recruiting |
NCT04239092 -
9-ING-41 in Pediatric Patients With Refractory Malignancies.
|
Phase 1 | |
Active, not recruiting |
NCT03208387 -
Understanding the Late Effects of Surviving a Pediatric Brain Tumor
|
||
Recruiting |
NCT05528939 -
Feasibility/Acceptability of Attentional-Control Training in Survivors
|
N/A |